Drug Combination Details

General Information of the Combination (ID: C36915)
Name Betulin   NP Info  + Sorafenib   Drug Info 
Structure +
Disease
Hepatocellular carcinoma [ICD-11: 2C12]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Up-regulation Expression SREBF1  Molecule Info 
Pathway MAP
                    In-vitro Model Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
Huh-7 CVCL_0336 Adult hepatocellular carcinoma Homo sapiens
SMMC-7721 CVCL_0534 Hepatocellular carcinoma Homo sapiens
BEL-7402 CVCL_5492 Human hepatocellular carcinoma Homo sapiens
MHCC97-L CVCL_4973 Adult hepatocellular carcinoma Homo sapiens
MHCC97-H CVCL_4972 Adult hepatocellular carcinoma Homo sapiens
                    In-vivo Model To establish the animal model, HCC cells were injected subcutaneously into nude mice.
                    Experimental
                    Result(s)		 SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.
References
Reference 1 SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis. 2019 Sep 11;10(9):672.
 Download Picture         KEGG Link